https://www.biopharmawatch.com/news/ALNY/alnylam-esc-congress-2026-data BiopharmaWatch en 2026-08-30T12:23:00.000Z Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings https://www.biopharmawatch.com/news/BMY/bmy-camzyos-long-term-efficacy-esc-congress-2026 BiopharmaWatch en 2026-08-29T15:00:00.000Z Bristol Myers Squibb Presents Data Up to Five Years Reinforcing the Long-Term Efficacy and Safety of Camzyos (mavacamten) in Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/CYTK/cytokinetics-acacia-hcm-maple-hcm-results-esc-2026 BiopharmaWatch en 2026-08-29T14:30:00.000Z Cytokinetics Announces Additional Results from ACACIA-HCM and MAPLE-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology (ESC) Congress 2026 https://www.biopharmawatch.com/news/TENX/tenax-therapeutics-phase-3-level-results-esc-congress-2026 BiopharmaWatch en 2026-08-29T12:21:00.000Z Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 https://www.biopharmawatch.com/news/TAK/takeda-fda-approval-mimrylo-polycythemia-vera BiopharmaWatch en 2026-08-28T22:40:00.000Z Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera https://www.biopharmawatch.com/news/AIDX/2020-biolabs-investor-webinar-september-2026 BiopharmaWatch en 2026-08-28T22:26:00.000Z 20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity https://www.biopharmawatch.com/news/TRIB/trinity-biotech-diagnostics-update-august-2026 BiopharmaWatch en 2026-08-28T21:15:00.000Z Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update https://www.biopharmawatch.com/news/OGEN/oragenics-clinical-progress-regulatory-update BiopharmaWatch en 2026-08-28T20:25:00.000Z Oragenics Reports Continued Clinical Progress, Provides Regulatory and NYSE American Listing Update https://www.biopharmawatch.com/news/ZBH/zimmer-biomet-quarterly-dividend-q3-2026 BiopharmaWatch en 2026-08-28T20:15:00.000Z Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2026 https://www.biopharmawatch.com/news/SHPH/shuttle-pharmaceuticals-nasdaq-noncompliance-letter BiopharmaWatch en 2026-08-28T20:06:17.000Z Shuttle Pharmaceuticals Holdings, Inc. Announces Receipt of NASDAQ Noncompliance Letter https://www.biopharmawatch.com/news/TXG/10x-genomics-patent-infringement-verdict-parse-biosciences BiopharmaWatch en 2026-08-28T18:38:00.000Z 10x Genomics Wins Patent Infringement Verdict Against Parse Biosciences https://www.biopharmawatch.com/news/UNH/am-best-affirms-unitedhealth-group-credit-ratings BiopharmaWatch en 2026-08-28T18:27:00.000Z AM Best Affirms Credit Ratings of UnitedHealth Group Incorporated and Its Subsidiaries https://www.biopharmawatch.com/news/NTRA/natera-susan-g-komen-partnership-breast-cancer BiopharmaWatch en 2026-08-28T15:03:00.000Z Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer https://www.biopharmawatch.com/news/CRSP/crispr-therapeutics-phase-1a-data-ctx310-esc-2026 BiopharmaWatch en 2026-08-28T14:31:00.000Z CRISPR Therapeutics Presents Phase 1a Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and LDL Lowering at ESC Congress 2026 https://www.biopharmawatch.com/news/AGEN/agenus-bot-bal-survival-mss-colorectal-cancer BiopharmaWatch en 2026-08-28T14:07:00.000Z Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism https://www.biopharmawatch.com/news/NTHI/neonc-phase-2a-success-registration-pathway BiopharmaWatch en 2026-08-28T14:07:00.000Z NeOnc’s Phase 2A Success Could Set the Stage for Something Much Bigger https://www.biopharmawatch.com/news/IGC/ascendiant-capital-markets-raises-igc-pharma-price-target BiopharmaWatch en 2026-08-28T13:40:00.000Z Ascendiant Capital Markets Raises IGC Pharma Price Target to $6.00, Citing CALMA Progress and Q4 2026 Topline Catalyst https://www.biopharmawatch.com/news/COSM/cosmos-health-strengthens-balance-sheet-capital-structure BiopharmaWatch en 2026-08-28T13:30:00.000Z Cosmos Health Strengthens Balance Sheet and Streamlines Capital Structure; Retires $8M ATW Convertible Note One Year Ahead of Maturity, Eliminating Further Dilution From Conversions https://www.biopharmawatch.com/news/TNON/tenon-medical-3m-private-placement-offering BiopharmaWatch en 2026-08-28T13:00:00.000Z WallachBeth Capital Announces Tenon Medical Pricing of $3M Private Placement Offering https://www.biopharmawatch.com/news/VVOS/vivos-therapeutics-south-palm-cardiovascular-agreements BiopharmaWatch en 2026-08-28T12:45:00.000Z Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center